Combined perfusion MRI and MR spectroscopy in multiple sclerosis

Combined perfusion MRI and MR spectroscopy in multiple sclerosis - MRI and MRS in MS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30006

Enrollment

Registered

2006-12-04

Start date

2006-09-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple sclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusioncriteria patients: - age 18-60 years - diagnosis of multiple sclerosis according to the McDonald-criteria (McDonald et al., 2001). - written informed consent;Inclusioncriteria controls: - age eightteen and older - written informed consent

Exclusion criteria

Exclusion criteria: Exclusioncriteria patients: - use of systemic corticosteroids in the eight weeks before start of the study - use of immunomodulating therapies (interferon-ß, glatiramer acetate) - a history of cerebral pathology other than MS (brain infarct, brain haemorrhage, Parkinson's disease, Alzheimer's disease, cerebral vasculitis, brain absces) - Diabetes mellitus;Exclusiecriteria controls: - a history of cerebral pathology (brain infarct, brain haemorrhage, Parkinson's disease, Alzheimer's disease, cerebral vasculitis, brain absces) - Diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Primary endpoints: - The difference in measures of cerebral perfusion between the groups of RRMS, SPMS, PPMS patients and healthy controls. - The difference in measures of cerebral metabolism (as measured with MR spectroscopy) between the groups of RRMS, SPMS, PPMS patients and healthy controls. - The correlation between measures of cerebral perfusion and cerebral metabolism in the groups RRMS, SPMS, PPMS and healthy control persons.	—

Measure

Time frame

Primary endpoints: - The difference in measures of cerebral perfusion between the groups of RRMS, SPMS, PPMS patients and healthy controls. - The difference in measures of cerebral metabolism (as measured with MR spectroscopy) between the groups of RRMS, SPMS, PPMS patients and healthy controls. - The correlation between measures of cerebral perfusion and cerebral metabolism in the groups RRMS, SPMS, PPMS and healthy control persons.

—

Secondary

Measure	Time frame
Secondary endpoints: - the correlation between clinical measures of disability with measures of cerebral perfusion - the correlation of clinical measures of disability with measures of cerebral metabolism	—

Countries

Netherlands

Outcome results